|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Sales | |||||
| Costs, Expenses and Other | |||||
| Cost of sales | |||||
| Selling, general and administrative | |||||
| Research and development | |||||
| Restructuring costs | |||||
| Other (income) expense, net | |||||
| Total costs, expenses and other | |||||
| Income Before Taxes | |||||
| Taxes on Income | |||||
| Net Income from Continuing Operations Attributable to Merck & Co., Inc. | |||||
| Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | |||||
| Net Income | |||||
| Less: Net Income Attributable to Noncontrolling Interests | |||||
| Net Income Attributable to Merck & Co., Inc. | |||||
| Income from Continuing Operations (in dollars per share) | |||||
| Income from Discontinued Operations (in dollars per share) | |||||
| Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | |||||
| Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) |
Loading...
